89Zr-Patritumab deruxtecan

Phase 2

Daiichi Sankyo (DSKYF)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

DSKYFPhase 2$34.8B

89Zr-Patritumab deruxtecan Phase 2 Est. Readout

89Zr-Patritumab deruxtecan• Non-Small Cell Lung Carcinoma16

Q2 2027~QConfirmed

CT.gov

00%

Competitive Landscape

3 competitors in Non-Small Cell Lung Carcinoma

LLYPaclitaxel (Taxane)

Phase 3

SGENSGN-15, Docetaxel

Drug Information

Target Indication

Non-Small Cell Lung Carcinoma

Clinical Trial

NCT06222489

Last updated: 8/20/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

DSKYF

Daiichi Sankyo

Healthcare•North America•NASDAQ

Related Pipeline

olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tabletsPhase 3

Essential Hypertension

Platinum ChemotherapyPhase 3

Non-small Cell Lung Cancer

Vitamin K antagonistPhase 3

Atrial Fibrillation

AmrubicinPhase 3

Small Cell Lung Cancer

Olmesartan medoxomil plus amlodipinePhase 3

Hypertension

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts